Selecta Biosciences, Inc. Ein kurzer Steckbrief.
Ein weiterer Finanzierungspflegefall!
Gut, jetzt ist der Kurs unten und die Finanzierung soll zu 1,5$ pro Aktie durchgeführt werden.
Aktien out vor 22,434,212 shares, danach sollen 45,471,776 shares werden.
As of November 2, 2018 , the registrant had 22,434,212 shares of common stock
We are offering 20,000,000 shares of our common stock.
We have granted the underwriters an option for a period of 30 days to purchase up to an additional 3,000,000 shares of our common stock
42,471,776 shares (or 45,471,776 shares if the underwriters exercise in full their option to purchase additional shares)
Sprich eine MK bei 1,5$ um cash!
As of December 31, 2018, Selecta Biosciences, Inc. had $37.4 million of cash and cash equivalents
We estimate that the net proceeds from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $27.9 million or $32.1 million if the underwriters exercise their option to purchase additional shares of common stock in full.
Selecta verbrennt natürlich auch ein Haufen Kohle!
We incurred net losses of $50.7 million and $45.8 million for the nine months ended September 30, 2018 and 2017
Vermutlich werden sie in 2019 weiter Kapital benötigen und auch besorgen.
Weiter haben sie noch:
The number of shares of our common stock to be outstanding immediately after this offering is based on 22,471,776 shares of our common stock outstanding as of December 31, 2018 and excludes:
•4,103,979 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2018 at a weighted average exercise price of $9.20 per share;
•176,432 shares of common stock issuable upon exercise of warrants outstanding as of December 31, 2018, at a weighted average exercise price of $17.32 per share;
•175,000 shares of common stock issuable upon vesting of restricted stock units outstanding as of December 31, 2018;
•1,037,031 shares of common stock reserved for issuance under our 2016 Incentive Award Plan, or the 2016 Plan, as of December 31, 2018, as well as shares that become available pursuant to provisions in our 2016 Plan that automatically increase the share reserve under the 2016 Plan; and
•539,894 shares of common stock reserved for issuance under our 2016 Employee Stock Purchase Plan, or the 2016 ESPP, as of December 31, 2018, as well as shares that become available pursuant to provisions in our 2016 ESPP that automatically increase the share reserve under the 2016 ESPP.
Steht alles in den SEC Q3 und KE
https://www.nasdaq.com/symbol/selb/sec-filings
